MAI Capital Management Cuts Stock Position in Lineage Cell Therapeutics, Inc. $LCTX

MAI Capital Management decreased its position in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 90.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 64,391 shares of the company's stock after selling 593,288 shares during the period. MAI Capital Management's holdings in Lineage Cell Therapeutics were worth $29,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Two Sigma Advisers LP grew its stake in shares of Lineage Cell Therapeutics by 312.2% in the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company's stock worth $44,000 after buying an additional 65,864 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Lineage Cell Therapeutics in the 4th quarter worth approximately $152,000. Barclays PLC grew its stake in shares of Lineage Cell Therapeutics by 10.8% in the 4th quarter. Barclays PLC now owns 234,069 shares of the company's stock worth $118,000 after buying an additional 22,769 shares during the last quarter. Comerica Bank grew its stake in shares of Lineage Cell Therapeutics by 220.0% in the 4th quarter. Comerica Bank now owns 800,000 shares of the company's stock worth $402,000 after buying an additional 550,000 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Lineage Cell Therapeutics in the 4th quarter worth approximately $46,000. Hedge funds and other institutional investors own 62.47% of the company's stock.

Lineage Cell Therapeutics Price Performance

Shares of NYSEAMERICAN:LCTX traded up $0.05 during midday trading on Friday, hitting $1.34. The company had a trading volume of 3,107,364 shares, compared to its average volume of 1,464,753. The company has a market cap of $306.00 million, a price-to-earnings ratio of -7.44 and a beta of 1.66. Lineage Cell Therapeutics, Inc. has a 12-month low of $0.37 and a 12-month high of $1.42. The company has a fifty day moving average of $1.10 and a two-hundred day moving average of $0.77.

Wall Street Analysts Forecast Growth

LCTX has been the topic of several recent research reports. D. Boral Capital restated a "buy" rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research note on Wednesday, August 27th. HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday, June 23rd. Four research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Lineage Cell Therapeutics has an average rating of "Buy" and a consensus price target of $4.25.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.